EULAR 2023

Let's go for early treatment in axial envolvement?

Systemic inflammation in SpA /PsA

Treatment opportunities and what is new in PsA

Pushing the brake with a new treatment strategy

Risk factors and prevention of arthritis

Which is the ideal instrument to assess disease activity in axSpA?

Secukinumab vs Adalimumab on radiographic progression in axSpA

Should we follow chronic back pts. suspected of early axSpA?

What is early axSpA?

Definition of early axSpA

The effect of IL-17 inhibition on radiographic progression

Clinically relevant findings for SpA detection

Do NSAIDs modify the appearance of SIJ MRI?

Data from clinical studies relevant for daily practice

Factors associated with remission in early peripheral spondyloarthritis

Los AINES modifican la expresión de la RM de sacrolíacas?

Daten aus klinischen Studien für die tägliche Praxis

Definition consensuelle ASAS de la spondyloarthrite périphérique

Effekt der IL-17 Inhibition auf die Röntgenprogression

Klinisch wichtige Befunde zur SpA-Erkennung

Secukinumab vs Adalimumab dans la progression radiographique des SpA axiales

Deberíamos seguir a los pacientes con dolor lumbar crónico con sospecha de EspAax?

Facteurs associés à l’obtention d’une rémission dans la SpA périphérique débutante

Was ist frühe axSpA?

Qual'e lo strumento ideale per la valutazione di attività di malattia nelle spondiloartriti?

Points to consider in PsA!

Systemic inflammation objectively detectable

MTX + Biologica in PsA

Differences between sex and gender in PsA

Early therapy in PsA is predictive

Dual inhibition of IL-17A and IL-17F: a new option in PsA

Deucravacitinib - effective and safe

Higher comorbiditiy burden in PsA vs RA

No need of MTX again and again and...

Frühe Therapie bei PsA prädiktiv

Differenze di genere nell'Artrite Psoriasi

Nicht schon wieder MTX...

Points to consider bei PsA

Mehr Komorbiditäten bei PsA als bei RA

Deucravacitinib - effektiv und sicher

MTX + Biologica bei PsA

Sytemische Inflammation objektiv erkennbar

Duale Inhibition A und F: neue Option für PsA

Prevention - should we treat pre-arthitis?

Update on JAKi safety

Pushing the brake with a new treatment strategy

Putting a focus on TDM

Keeping an eye on the lung!

Preventing RA

Peresolimab - a new therapeutic principle in rheumatology?

Lung involvement in RA

Pooled safety analysis of filgotinib

Corticoid bridging in RA - useful and safe

What is new in RA?

The IL-23 pathway

Major adverse cardiovascular events in patients on JAK-inhibitors

Difficult to treat and poly-refractory RA in a clinical setting

Peresolimab - ein neues Therapieprinzip für die Rheumatologie?

Tratamiento con glucocorticoides al inicio del FAME - útil y segura!

AR difícil de tratar y polirrefractaria en la practica clinica

Kardiovaskulære hendelser hos pasienter behandlet med JAK-hemmere

Measurement of anti-drug antibodies in rheumatology

To stop or not to stop TNF-inhibitors after pregnancy diagnosis in women with chronic rheumatic inflammatory diseases?

Overview of treatment recommendations in PsA and axSpA

Immunogenicity in Adalimumab - real-world data

Arthritis therapy under checkpoint-inhibition

Incidence of ILD in patients with RA and PsA

Development of EMM in SpA patients treated with upadacitinib

Aspetti principali delle raccomandazioni per l'Artrite Psoriasica e le Spondiloartriti

Messung von Anti-drug Antibodies in der Rheumatologie

Insidens av interstitiell lungesykdom hos pasienter med RA og PsA

Immunogenisitet hos pasienter behandlet med adalimumab – data fra NOR-DMARD

Therapie der Arthritis unter Checkpoint-Inhibitoren

Desarrollo de MEM en pacientes con EspA tratados con upadacitinib

Interrompere o non interrompere gli anti-TNF dopo la diagnosi di gravidanza nelle donne con malattie infiammatorie reumatiche croniche?

Childhood infections, perinatal factors, and the risk of developing Ankolysing Spondylitis

Cardiovascular disease and long-term use of NSAIDs in Ankolysing Spondylitis

Infezioni infantili, fattori perinatali e rischio di sviluppare spondilite anchilosante

Rischio cardiovascolare e utilizzo prolungato di fans nella Spondilite anchilosante

New promising strategies in Lupus and Sjögren's Syndrome

JAK inhibition and BTK-JAK inhibition in lupus

Update on CAR-T cells!

1-year data on CAR-T cell therapy in lupus

Telitacicept in lupus

1-Jahres Daten zur CAR-T-Zell Therapie beim Lupus

JAK-Inhibition und BTK-JAK-Inhibition bei Lupus

Aktuelles zur CAR-T-Zelltherapie!

Telitacicept beim Lupus

Telitacicept in Sjögren's Syndrome

Telitacicept beim Sjögren Syndrom

IL-17 isoforms in enthesitis

COVID-19: a pandemic with a long tail

IL-17-Isoformen bei Enthesitis